These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 24986837)

  • 1. Uncertainty in assessing impact of drug-drug interactions on oxycodone metabolite patterns.
    DePriest AZ; Puet BL; Heltsley R; Robert T; Black DL
    J Anal Toxicol; 2014 Sep; 38(7):462. PubMed ID: 24986837
    [No Abstract]   [Full Text] [Related]  

  • 2. Urine drug testing for oxycodone and its metabolites as a tool for drug-drug interactions?
    Mikus G
    J Anal Toxicol; 2015; 39(1):81-2. PubMed ID: 25288721
    [No Abstract]   [Full Text] [Related]  

  • 3. Response to urine drug testing for oxycodone and its metabolites as a tool for drug-drug interactions.
    Elder NM; Atayee RS; Best BM; Ma JD
    J Anal Toxicol; 2015; 39(1):80. PubMed ID: 25288719
    [No Abstract]   [Full Text] [Related]  

  • 4. Authors' reply.
    Elder NM; Atayee RS; Best BM; Ma JD
    J Anal Toxicol; 2014 Sep; 38(7):463. PubMed ID: 24986838
    [No Abstract]   [Full Text] [Related]  

  • 5. Observations of urinary oxycodone and metabolite distributions in pain patients.
    Elder NM; Atayee RS; Best BM; Ma JD
    J Anal Toxicol; 2014 Apr; 38(3):129-34. PubMed ID: 24523296
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Observations on the urine metabolic ratio of oxymorphone to oxycodone in pain patients.
    Yee DA; Best BM; Atayee RS; Pesce AJ
    J Anal Toxicol; 2012 May; 36(4):232-8. PubMed ID: 22511697
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Urine testing for norcodeine, norhydrocodone, and noroxycodone facilitates interpretation and reduces false negatives.
    Cone EJ; Zichterman A; Heltsley R; Black DL; Cawthon B; Robert T; Moser F; Caplan YH
    Forensic Sci Int; 2010 May; 198(1-3):58-61. PubMed ID: 20036472
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Determination of oxycodone and its major metabolites noroxycodone and oxymorphone by ultra-high-performance liquid chromatography tandem mass spectrometry in plasma and urine: application to real cases.
    Pantano F; Brauneis S; Forneris A; Pacifici R; Marinelli E; Kyriakou C; Pichini S; Busardò FP
    Clin Chem Lab Med; 2017 Aug; 55(9):1324-1331. PubMed ID: 28080998
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tentative identification of novel oxycodone metabolites in human urine.
    Moore KA; Ramcharitar V; Levine B; Fowler D
    J Anal Toxicol; 2003 Sep; 27(6):346-52. PubMed ID: 14516487
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prescription Opioids. V. Metabolism and Excretion of Oxymorphone in Urine Following Controlled Single Dose Administration.
    DePriest AZ; Heltsley R; Black DL; Mitchell JM; LoDico C; Flegel R; Cone EJ
    J Anal Toxicol; 2016 Oct; 40(8):566-574. PubMed ID: 27405370
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prescription opioids. I. Metabolism and excretion patterns of oxycodone in urine following controlled single dose administration.
    Cone EJ; Heltsley R; Black DL; Mitchell JM; Lodico CP; Flegel RR
    J Anal Toxicol; 2013 Jun; 37(5):255-64. PubMed ID: 23609023
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determination of oxycodone, noroxycodone and oxymorphone by high-performance liquid chromatography-electrospray ionization-tandem mass spectrometry in human matrices: in vivo and in vitro applications.
    Fang WB; Lofwall MR; Walsh SL; Moody DE
    J Anal Toxicol; 2013; 37(6):337-44. PubMed ID: 23743505
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monitoring oxycodone use in patients with chronic pain: analysis of oxycodone and metabolite excretion in saliva and urine.
    Moy KV; Ma JD; Morello CM; Atayee RS; Best BM
    J Opioid Manag; 2014; 10(1):47-56. PubMed ID: 24604569
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Determination of oxycodone and its major metabolites in haematic and urinary matrices: Comparison of traditional and miniaturised sampling approaches.
    Protti M; Catapano MC; Samolsky Dekel BG; Rudge J; Gerra G; Somaini L; Mandrioli R; Mercolini L
    J Pharm Biomed Anal; 2018 Apr; 152():204-214. PubMed ID: 29414014
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The pharmacokinetics of oxycodone in uremic patients undergoing renal transplantation.
    Kirvela M; Lindgren L; Seppala T; Olkkola KT
    J Clin Anesth; 1996 Feb; 8(1):13-8. PubMed ID: 8695073
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hydrophilic interaction LC-MS/MS analysis of opioids in urine: significance of glucuronide metabolites.
    French D; Wu A; Lynch K
    Bioanalysis; 2011 Dec; 3(23):2603-12. PubMed ID: 22136049
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cancer cachexia raises the plasma concentration of oxymorphone through the reduction of CYP3A but not CYP2D6 in oxycodone-treated patients.
    Naito T; Tashiro M; Ishida T; Ohnishi K; Kawakami J
    J Clin Pharmacol; 2013 Aug; 53(8):812-8. PubMed ID: 23733622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Degradation of Opioids and Opiates During Acid Hydrolysis Leads to Reduced Recovery Compared to Enzymatic Hydrolysis.
    Sitasuwan P; Melendez C; Marinova M; Mastrianni KR; Darragh A; Ryan E; Lee LA
    J Anal Toxicol; 2016 Oct; 40(8):601-607. PubMed ID: 27702939
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is it time to drug test your chronic pain patient?
    McBane S; Weigle N
    J Fam Pract; 2010 Nov; 59(11):628-33. PubMed ID: 21060901
    [No Abstract]   [Full Text] [Related]  

  • 20. Pharmacokinetic-pharmacodynamic relationships of controlled-release oxycodone.
    Kaiko RF; Benziger DP; Fitzmartin RD; Burke BE; Reder RF; Goldenheim PD
    Clin Pharmacol Ther; 1996 Jan; 59(1):52-61. PubMed ID: 8549034
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.